075586725195  |  Set Home  |  Favorite  |  中文
Case report
Case report
Case4# The PR patient of severe Hodgkin lymphoma
Date: 2019-10-18

A 28 year-old woman with Hodgkin's lymphoma…

Cancer History:

First diagnosis of cancer: 2011   Cancer type: Hodgkin’s Lymphoma nodular sclerosis, stage IIIa

First recurrence date: 01.2016     Sites: liver, abdomen, LN

Refractory or persistent disease sites: liver, abdomen, lung, LN, hepatosplenomegaly

Therapy gone through: Surgery: No 

Chemotherapy 8 cycles, 4 ABVD, 4 BVD regimen, gemcitabine; 

Radiotherapy: yes, post-radiatherapy pulmonary fibrosis; ABMT: 5.2016 

Targeted drugs: bendamustine   Immunotherapy: Brentuximab, Nivoluma   others: 

Clinical Trial Number: NCT02274584 (4SCAR30273); enrolled date: 18/07/2019

Interventions: 4SCAR (CD19, CD22, PSMA)

            Consolidation: EIE 

CRS Grade:1 ; other side effects:  knee joint pain 

Treatment response: PR     Quality of Life: improved

Progression-free interval: 2 months 

Current status: Alive with disease

Disease images before and after CART/EIE treatment (with time)

Link of published paper, youtube, patient’s feedback letter: pending

ADD: 深圳市南山区粤兴二道6号虚拟大学园重点实验室平台二层   TEL: 075586725195   Email: gimi_trials@szgimi.org

Copyright © 2016 Shenzhen Genoimmune Medical Institute all rights reserved.